AIMS AND BACKGROUND: The aim of this study is to determine prognostic factors that influence further outcome in patients with glioma. METHODS: Between 01/2002 and 08/2008, 153 patients with malignant gliomas of WHO-grade 3 or 4 who were treated with external beam radiotherapy with or without chemotherapy. RESULTS: In univariate analysis, following factors were ascertained as statistically significant prognostic parameters: grade (p = 0.000), time between operation and radiotherapy >24 days (p = 0.044) for progression-free survival; grade (p = 0.000), age<58 years (p = 0.001), extent of surgery (p = 0.011), time between operation and radiotherapy >24 days (p = 0.009), overall treatment time >68 days (p = 0.003), use of chemotherapy (p = 0.015) for overall survival. A longer time period between resection and start of radiotherapy showed to be associated with improved outcome. After multivariate analysis, only grade (p = 0.000) remained a statistically significant factor for progression-free and grade (p = 0.000) and use of chemotherapy (p = 0.031) for overall survival. CONCLUSIONS: We were able to recognize grade and use of chemotherapy as statistically significant prognostic determinants, but not time intervals or overall treatment time.
AIMS AND BACKGROUND: The aim of this study is to determine prognostic factors that influence further outcome in patients with glioma. METHODS: Between 01/2002 and 08/2008, 153 patients with malignant gliomas of WHO-grade 3 or 4 who were treated with external beam radiotherapy with or without chemotherapy. RESULTS: In univariate analysis, following factors were ascertained as statistically significant prognostic parameters: grade (p = 0.000), time between operation and radiotherapy >24 days (p = 0.044) for progression-free survival; grade (p = 0.000), age<58 years (p = 0.001), extent of surgery (p = 0.011), time between operation and radiotherapy >24 days (p = 0.009), overall treatment time >68 days (p = 0.003), use of chemotherapy (p = 0.015) for overall survival. A longer time period between resection and start of radiotherapy showed to be associated with improved outcome. After multivariate analysis, only grade (p = 0.000) remained a statistically significant factor for progression-free and grade (p = 0.000) and use of chemotherapy (p = 0.031) for overall survival. CONCLUSIONS: We were able to recognize grade and use of chemotherapy as statistically significant prognostic determinants, but not time intervals or overall treatment time.
Authors: Seunggu J Han; Dario J Englot; Harjus Birk; Annette M Molinaro; Susan M Chang; Jennifer L Clarke; Michael D Prados; Jennie W Taylor; Mitchel S Berger; Nicholas A Butowski Journal: Neurosurgery Date: 2015-08 Impact factor: 4.654
Authors: Irene Rodríguez-Hernández; Juan Luis Garcia; Angel Santos-Briz; Aurelio Hernández-Laín; Jose María González-Valero; Juan Antonio Gómez-Moreta; Oscar Toldos-González; Juan Jesús Cruz; Javier Martin-Vallejo; Rogelio González-Sarmiento Journal: PLoS One Date: 2013-09-20 Impact factor: 3.240
Authors: Irene Rodríguez-Hernández; Marta Vázquez-Cedeira; Angel Santos-Briz; Juan L García; Isabel F Fernández; Juan A Gómez-Moreta; Javier Martin-Vallejo; Rogelio González-Sarmiento; Pedro A Lazo Journal: BMC Clin Pathol Date: 2013-10-01
Authors: Amedeo A Azizi; Simon Paur; Alexandra Kaider; Karin Dieckmann; Andreas Peyrl; Monika Chocholous; Thomas Czech; Irene Slavc Journal: Strahlenther Onkol Date: 2018-01-18 Impact factor: 3.621
Authors: Samantha M Buszek; Karine A Al Feghali; Hesham Elhalawani; Neil Chevli; Pamela K Allen; Caroline Chung Journal: Sci Rep Date: 2020-03-18 Impact factor: 4.379
Authors: Kwanza T Warren; Linxi Liu; Yang Liu; Myla S Strawderman; Ali H Hussain; Heather M Ma; Michael T Milano; Nimish A Mohile; Kevin A Walter Journal: CNS Oncol Date: 2020-10-28